Shire buys US drugs delivery firm for pounds 105m
Wednesday 26 February 1997
The news came as Core Group, a company specialising in sustained release drug delivery products, announced that its pounds 73m stock market flotation had been "heavily oversubscribed" at 250p a share.
To part finance the Pharmavene deal and other acquisitions being contemplated, Shire is raising pounds 11.5m by way of a one-for-10 placing and offer at 214p a share. The group is also understood to be in negotiations for the purchase of an unnamed company in Europe and a product range in the UK for total of pounds 14m.
Despite the flood of new equity, the share price dropped just 3.5p to 234p yesterday as analysts welcomed the deal and news of lower-than-expected losses of pounds 105,000 in the latest six months. Dr Rolf Stahel, Shire's chief executive, said it had effectively achieved break-even in six months, rather than the 12 months forecast by the market.
Pharmavene gives Shire another 11 potential new products, taking the pipeline to 30. The US group has created a high-throughput method of screening how well particular drug formulations penetrate human cells in the laboratory. It is applying the results in 11 projects to develop technologies for the delivery and release of drugs more effectively into the body.
The lead product is Carbatrol, a controlled release form of carbamazepine, a drug used in the treatment of epilepsy. Carbatrol, which is licensed to Athena, part of the Irish drugs delivery group Elan, could be launched later this year. If successful, it would compete directly with Novartis' Tegretol drug, which had sales of $340m in 1994.
Another product under development is a more efficient version of Glaxo Wellcome's Zovirax anti-herpes drug. But the bigger potential could come from an oral form of Calcitonin, used for the treatment of brittle bones, which could attack a world market currently put at $5bn.
Separately, Oxford Molecular, a biotechnology group, announced that it was investing pounds 500,000 in Cambridge Combinatorial, a new drug research company run by Allan Marchington, the brother of Oxford's chief executive Tony Marchington.
Oxford will take a 20 per cent stake in Cambridge. The new company plans to use combinatorial chemistry to supply potential drug prospects to other drug and biotech groups. It claims it will have an edge on similar companies by providing a narrower range of compounds for screening as new drug prospects.
International Women's Day 2014: The shocking statistics that show why it is still so important
Singapore sting: Sky-high prices are pushing locals to the edge of affordability
International Women’s Day: 'When a man gives his opinion, he's a man. When a woman gives her opinion, she's a bitch' - feminist quotes from female icons to inspire you
International Women's Day 2014: Cherie Blair - ‘Today is a chance to see how far we still have to go’
Dead woman's body found sitting in a car after six years after direct debits ran $54,000 bank account dry
Britain's top vet sparks controversy with call for ban on slashing animals' throats in 'ritual' slaughters for halal and kosher meat products
Ukraine crisis: Russia dismisses '3am ultimatum' as 'total nonsense'
If you're horrified by a flame-roasted dog, you should be shocked at a hog roast
Poor 'live like animals' says Boris's privately educated sister after going on 'poverty safari'
White people become less racist just by moving to more diverse areas, study finds
Exclusive: Impact of immigrants on British workers ‘negligible’
- 1 International Women's Day 2014: The shocking statistics that show why it is still so important
- 2 Orgasm machine to deliver climax at the push of a button
- 3 Singapore sting: Sky-high prices are pushing locals to the edge of affordability
- 4 Liam Neeson turned down James Bond role because late wife Natasha Richardson said she wouldn't marry him if he took it
- 5 Dead woman's body found sitting in a car after six years after direct debits ran $54,000 bank account dry
iJobs Money & Business
£12000 per annum: Inspiring Interns: The company works with Tier 1 FTSE 100 Ba...
£32000 - £36000 per annum + generous benefits: Pro-Recruitment Group: * TAX * ...
£37000 - £40000 per annum + £20000 benefits package: Pro-Recruitment Group: **...
£30000 - £35000 per annum + generous benefits: Pro-Recruitment Group: Mixed Ta...